NCT01156571View on ClinicalTrials.gov

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

PHASE3CompletedINTERVENTIONAL
Enrollment

11,145

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
AtherosclerosisPercutaneous Coronary InterventionAcute Coronary Syndrome
Interventions
DRUG

cangrelor P2Y12 (platelet) inhibitor

DRUG

Clopidogrel - 300 or 600 mg (study arm)

Over encapsulated tablets.

DRUG

Clopidogrel 600 mg post cangrelor

over-encapsulated clopidogrel (600 mg)

Trial Locations (1)

29621

Anderson Area Medical Center, Anderson

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY